Sentences with phrase «in randomized phase»

Immune Design entered into a clinical trial collaboration with Genentech, a member of the Roche Group, to evaluate the safety and efficacy of its CMB305 cancer immunotherapy product candidate combined with the investigational cancer immunotherapy atezolizumab in a randomized Phase 2 trial in patients with soft tissue sarcoma.

Longitudinal study of the psoriasis - associated skin microbiome during therapy with ustekinumab in a randomized Phase 3b clinical trial — Michael Loesche — Journal of Investigative Dermatology

«There is a significant possibility that local therapy, such as consolidative radiation, may become an important part of the management of limited metastatic NSCLC patients, but this validation must take place in randomized phase III studies.

Not exact matches

In households where women between the ages of 15 and 40 were pregnant, volunteer participants were administered either influenza vaccine or placebo as part of a randomized, placebo - controlled Phase 4 clinical trial.

The HYPO - RT - PC trial, a randomized multi-institutional phase III trial in Scandinavia, was designed to assess outcomes from highly accelerated extreme hypofractionation, which is delivered in smaller number of high doses — seven fractions of 6.1 Gy each in this study.

Luznik says that the researchers» next step will be to test the short course therapy in a phase III randomized clinical trial that would directly compare results in patients who receive the cyclophosphamide treatment with those who receive either a separate, experimental approach to prevent GVHD or the more traditional six - month immunosuppressive therapy.

He identified 193 Phase III randomized trials — the gold standard in clinical research — for analysis.

Two hundred twenty - five people with schizophrenia, schizoaffective disorder or a mood disorder participated in the phase 3 randomized double blind, placebo - controlled trial.

The study was a randomized phase II trial testing whether the addition of local treatment, in the form of consolidative radiation therapy, to the standard treatment of systemic therapy improved progression - free survival for patients with limited metastatic NSCLC.

TRINOVA - 1 was a randomized prospective phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) among 919 women with recurrent ovarian cancer patient from 179 sites in 32 countries.

In 2013, Dr. Schwartz and his colleagues launched the first large - scale, Phase II, randomized trial of selumetinib.

PRIME 2 is an international, phase III, randomized, controlled trial that set out to address the question of whether whole - breast radiotherapy can be omitted in carefully defined groups of older patients receiving appropriate therapy.

In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutationIn a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutationin combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutations.

The resveratrol clinical trial was a randomized, phase II, placebo - controlled, double blind study in patients with mild to moderate dementia due to Alzheimer's disease.

Treating patients with high - dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

This Phase 3 randomized, double - blind study included 763 adults with chronic HCV genotype 1 infection, a form of the virus found in up to 75 percent of infections, and compensated liver diseases, who had previously not responded or only partially responded to at least one course of peginterferon and ribavirin.

This study, «Final Results of Local - Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer,» is a multi-institutional, randomized Phase III trial of fractionation in locally advanced head and neRandomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer,» is a multi-institutional, randomized Phase III trial of fractionation in locally advanced head and nerandomized Phase III trial of fractionation in locally advanced head and neck cancer.

«To evaluate these findings in a group with only one HER2 treatment, we are currently analyzing data from another clinical trial, the GeparQuinto clinical trial, which is a randomized, phase III clinical trial evaluating two different neoadjuvant therapy regimens with a single anti-HER2 treatment [trastuzumab or lapatinib] for women with HER2 - positive breast cancer,» said Loibl.

A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

A Phase III Randomized Trial for Newly Diagnosed High Risk B - precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND # 73789, NSC # 606869) in the Very High Risk Stratum

A randoMized phAse II trIal of fulvestraNt wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin - dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial)

A Phase 3, Multicenter, Randomized, Double - Blind, Placebo - Controlled Study of AG - 120 in Previously - Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

A Phase 3 Open - label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation

A Phase 3 Open - Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3 - ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First - line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

14255: STAT3 Signaling During Chemo - Radiation for Squamous Cell Carcinoma of the Head and Neck 14340: A Phase II, Randomized, Open - Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) 14258: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

This led to initiate an overseas, randomized controlled registered phase I / II trial in humans including 70 chronic SCI patients.

A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT - Methylated (Tumor O6 - methylguanine DNA methyltransferase) Glioblastoma

14145: Phase II Randomized Trial of Transoral Surgical Resection Followed by Low - dose or Standard - dose IMRT in Resectable p16 + Locally Advanced Oropharynx Cancer

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma who have not received Prior VEGF Therapy

Phase 2 Randomized, Double - Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2 + Breast Carcinoma

Phase III Randomized, Placebo - Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy + / - One Year of Everolimus in Patients with High - Risk, Hormone Receptor - Positive and HER2 / neu Negative Breast Cancer.

Randomized, Open - Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum - Doublet Chemotherapy versus Platinum - Doublet Chemotherapy in Early Stage NSCLC

A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib Versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

A Phase III, Multicenter, Randomized, Placebo - Controlled, Double - Blind Study Of Atezolizumab (Anti − PD - L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

A Phase 3, Randomized, Open - Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed / Refractory Diffuse Large B Cell Lymphoma (ZUMA - 7)

A Phase III, Multicenter, Randomized, Placebo - Controlled Study of Atezolizumab (ANTI − PD - L1 Antibody) as Monotherapy and in Combination with Platinum - Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

A Phase III Randomized Open - Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid - Refractory Chronic Graft vs Host Disease after Allogenic Stem Cell Transplantation (REACH 3)

An Open - Label, Randomized, Phase 2 Dose - Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post - Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytopenia Myelofibrosis Previously Treated with Ruxolitinib

A Multicenter, Randomized, Open - label, 3 - Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan / Cetuximab or Infusional 5 - Fluorouracil (5 - FU) / Folinic Acid (FA) / Irinotecan (FOLFIRI) / Cetuximab with a Safety Lead - in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E - mutant Metastatic Colorectal Cancer

A Phase I - II Randomized Trial of a Combination of Nintedanib / Placebo in Combination with Induction Chemotherapy for Patients with Refractory or First Relapse Acute Myeloid Leukemia

Comparisons during the postintervention phase include randomized participants in active follow - up and at risk for an initial diagnosis of the relevant outcome.

A Randomized Phase 2 Study of Cediranib in Combination with Olaparib versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer

A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer

Risk - Stratified Randomized Phase III Testing of Blinatumomab (IND # 117467, NSC # 765986) in First Relapse of Childhood B - Lymphoblastic Leukemia (B - ALL)

In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patientsIn that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patientsin complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).

A Phase 3, Multicenter, Randomized, Open - Label Study of Guadecitabine (SGI - 110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

A Randomized Phase III Study of Brentuximab Vedotin (SGN - 35, IND # 117117) for Newly Diagnosed High - Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents